Meeting
2013 ASCO Annual Meeting
BEVATEM: Phase II study of bevacizumab (B) in combination with temozolomide (T) in patients (pts) with first-line metastatic uveal melanoma (MUM): Final results.
Authors
Sophie Piperno-Neumann
Institut Curie, Paris, France
Sophie Piperno-Neumann , Vincent Servois , Francois-Clement Bidard , Pascale Mariani , Corine Plancher , Alhassane Diallo , Nora Vago-Ady , Laurence Desjardins
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Melanoma/Skin Cancers
Clinical Trial Registration Number
2009-011751-46
Citation
J Clin Oncol 31, 2013 (suppl; abstr 9057)
DOI
10.1200/jco.2013.31.15_suppl.9057
Abstract #
9057
Poster Bd #
46D
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Aflibercept-LV5FU2 as first-line treatment of non-resectable metastatic colorectal cancers: Results of the FOLFA randomized phase II trial.
First Author: Jean-Louis Legoux
Poster
2017 ASCO Annual Meeting
Phase II multicenter, single arm, open label study of nivolumab (NIVO) in combination with ipilimumab (IPI) as first line in adult patients (pts) with metastatic uveal melanoma (MUM): GEM1402 NCT02626962.
First Author: Josep M. Piulats
Poster
2014 ASCO Annual Meeting
Phase II study evaluating ipilimumab as a single agent in the first-line treatment of adult patients (Pts) with metastatic uveal melanoma (MUM): The GEM-1 trial.
First Author: Jose Maria Piulats Rodriguez
Poster
2023 ASCO Annual Meeting
The efficacy and safety of tislelizumab plus bevacizumab and chemotherapy as first line therapy in patients with persistent, recurrent, or metastatic cervical cancer: A multicenter, phase II study.
First Author: Jianqing Zhu